Laparoscopic Single Anastomosis Sleeve Ileal Bypass Versus Laparoscopic Sleeve Gastrectomy for Morbid Obesity

Laparoscopic Single Anastomosis Sleeve Ileal Bypass Versus Laparoscopic Sleeve Gastrectomy for Morbid Obesity: A Randomized Trial

This study will compare two bariatric surgical interventions in terms of weight loss, gastroesophageal reflux, and effects on obesity-related comorbid conditions in morbidly obese patients.

Study Overview

• Status: Recruiting
• Conditions: Obesity, Morbid
• Intervention / Treatment: Procedure: Single anastomosis sleeve ileal bypass; Procedure: Sleeve gastrectomy

Detailed Description

Sleeve gastrectomy is an established therapeutic option for morbidly obese patients without preexisting gastroesophageal reflux disease. The novel single anastomosis sleeve ileal bypass (SASI) procedure is already introduced in Norway at a private high-volume bariatric hospital. The purpose of this study is to evaluate the effects of SASI in comparison to an established bariatric procedure, i.e. sleeve gastrectomy. The primary end point is 2-year changes in BMI after sleeve gastrectomy and SASI.

• Study Type: Interventional
• Enrollment (Estimated): 220
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Helene M Haug, MD; Phone Number: +47 22 11 80 80; Email: b31831@ous-hf.no

Study Locations

• Norway
  • Oslo, Norway, 4950
    • Recruiting
    • Oslo University Hospital
    • Contact: Helene M Haug, MD
  • Vestfold
    • Tønsberg, Vestfold, Norway, 3103
      • Recruiting
      • The Morbid Obesity Center, Vestfold Hospital Trust
      • Contact: Marius Svanevik, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 60 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Morbid obesity at referral for bariatric surgery (i.e. a body-mass index [BMI] of ≥35 kg/m2 with obesity-related comorbid conditions or ≥40 kg/m2 with or without such comorbidities).
2. Age 20-60 years.
3. Previous failed attempts of weight loss.
4. Norwegian speaking patients.

Exclusion Criteria:

1. BMI ≥55 kg/m2.
2. A history of major abdominal or bariatric surgery (excluding appendectomy, cholecystectomy, and sectio).
3. Established disabling cardiopulmonary disease, ongoing treatment for cancer, long-term steroid use, and conditions believed to be associated with poor adherence after surgery.
4. Previous or current gastroesophageal reflux symptoms with daily use of antireflux medication. Patients are also excluded if preoperative manometry identifies a hiatal hernia (≥4cm in axial length) or if preoperative upper endoscopy identifies esophagitis grade C or D (LA classification), peptic stricture, Barrett's esophagus, or esophageal carcinoma.
5. Achalasia
6. Pregnancy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Single anastomosis sleeve ileal bypass; A Single anastomosis sleeve ileal bypass procedure is performed.	Procedure: Single anastomosis sleeve ileal bypass; The abdominal cavity is entered directly (visual trocar) with or without the use of Verres needle. A 6-port set up and a liver retractor is utilized. A sleeve gastrectomy is performed as described below, but division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300cm from the ileocecal valve, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 3.0 cm of 45 mm stapler is used the anastomosis; completed with a 2-0 PDS running suture. The biliopancreatic limb is anchored to the sleeve 4 cm proximal to the anastomosis (non-resorbable V-loc 3-0). Fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.; Other Names: SASI
Active Comparator: Sleeve gastrectomy; A sleeve gastrectomy procedure is performed.	Procedure: Sleeve gastrectomy; In the laparoscopic sleeve gastrectomy, the abdominal cavity is entered directly with a visual trocar with or without the use of Verres needle. The set up includes a total of 5 ports. The Natanson liver retractor is utilized. The greater omentum is separated from the major side of the stomach from the pylorus to the angle of His. The left crus is visualized and the hiatus is inspected for the presence of hernia. A 36 French bougie is introduced and the stomach is divided along this from 4-5cm proximal to the pylorus to 1cm lateral to the angle of His using two purple cartridges (Medtronic Tri-Staple™ technology) followed by beige 60mm cartridges to the angle of His, 1 cm lateral to the esophagus. The sleeve is tested for leaks with instillation of 50ml methylene blue in the tube. The fascia defect is closed with suture for the port site where the specimen is extracted.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in body-mass index (BMI)	Weight in kilograms divided by the square of the height in meters after sleeve gastrectomy and SASI.	2 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in prevalence of esophagitis.	Changes in the prevalence of esophagitis as evaluated by upper endoscopy.	2 year
Change in prevalence of gastroesophageal reflux disease.	Changes in the prevalence of gastroesophageal reflux disease as evaluated by 24-hour pH measurements.	2 year
Complications	Complications during surgery, postoperative complications (within 6 weeks [100 days for deaths]) as defined by the Accordion severity grading system and long-term complications.	6 weeks (100 days for deaths), 2 year, 5 year
Obesity-related comorbid conditions.	Changes in obesity-related comorbid conditions.	2 year, 5 year
Vitamin concentrations	Changes in vitamin levels (A, B1, B6, B9, B12, C, D, K).	2 year, 5 year
Obesity-related symptoms	Obesity-related Problem scale	2 year, 5 year
Gastrointestinal symptoms	GSRS	2 year, 5 year
Gastroesophageal reflux disease symptoms	GERDq	2 year, 5 year
Bowel habits	Bowel habit questionnaire	2 year, 5 year
Revisional surgery	Revisional surgery rates in the two groups.	2 year, 5 year
Long-term changes in BMI	BMI (weight in kilograms divided by the square of the height in meters) after sleeve gastrectomy and SASI.	5 years
Health-related quality of life	The RAND 36-Item Short Form Health Survery is a self-reporting questionnaire. Items are scored from 0 (lowest score) to 100 (highest possible score).	2 year, 5 year
Body composition	Changes in percentage fat mass and lean mass; percentage change in bone mineral density in lumbar spine (L1-L4), femoral neck, and total hip as assessed by DEXA scan.	2 years

Collaborators and Investigators

• Sponsor: Oslo University Hospital
• Investigators: Principal Investigator: Torgeir T Søvik, MD, PhD, Oslo University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 17, 2023
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): December 1, 2031

Study Registration Dates

• First Submitted: May 9, 2022
• First Submitted That Met QC Criteria: November 3, 2022
• First Posted (Actual): November 10, 2022

Study Record Updates

• Last Update Posted (Actual): May 18, 2026
• Last Update Submitted That Met QC Criteria: May 14, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: bariatric surgery; procedure: sleeve gastrectomy; procedure: single anastomosis sleeve ileal bypass
• Additional Relevant MeSH Terms: Nutrition Disorders; Overnutrition; Body Weight; Overweight; Obesity; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Obesity, Morbid
• Other Study ID Numbers: 319260

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No